N/A N=82 Nitrous Oxide Use in Minor Procedures
Laceration · Abscess
Primary: FLACC Pain Scale — 8; 2 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=77 Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults
Gastroduodenal Ulcerations · Erosion
Primary: Degree of GI Injury at Day 15 — 23; 20; 11; 13 participants
Phase 2 N=72 A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis
Psoriasis · Plaque Psoriasis
Primary: Overall Disease Severity Score (Success) — 30.6; 0.0 percentage of participants — p=<0.001
Phase 3 N=213 Buprenorphine for Prisoners
Heroin Addiction
Primary: Number of Days of Heroin Use — 6.0; 6.4; 6.5; 4.0 days
Phase 3 N=221 A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)
Plaque Psoriasis
Primary: Proportion of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) — 44.5; 6.3 percentage of participants — p=<0.001
N/A N=102 Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial Single Photon Emission Computed Tomography
Coronary Artery Disease
Primary: Myocardial Perfusion SPECT Image Quality 12 Minutes — 1; 0; 8; 3 participants
N/A N=1,669 A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
Hepatitis B, Chronic
Primary: Single Nucleotide Polymorphisms (SNPs) Associated With HBeAg Seroconversion or Hepatitis B Surface Antigen (HBsAg) Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive…
N/A N=1,842 An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
Hepatitis B, Chronic
Primary: Percentage of Participants With Hepatitis B Virus Surface Antigen Clearance — 2; 5; 5; 10 Percentage of Participants
Phase 2 N=23 Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
Waldenstrom's Macroglobulinemia
Primary: Number of Participants With Adverse Events — 23 participants
Phase 4 N=1,302 Study of Adacel® Vaccine Administered to Persons 10 Years of Age
Tetanus · Diphtheria · Pertussis
Primary: Summary of Geometric Mean Titers of Anti-Pertussis Titers Following a Single Dose of Adacel® Vaccine — 30.1; 32.0; 232; 225 Titers (1/dilutions)
Phase 2 N=65 A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Mean Number of New Inflammatory MRI Lesions Per Monthly Scans — 0.4; 1.7 New Lesions — p=0.87
N/A N=1,347 A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy
Breast Cancer · Non-Small Cell Lung Cancer · Ovarian Cancer
Primary: Percentage of Participants With Febrile Neutropenia (FN) — 8; 8; 15; 9 percentage of participants
Phase 3 N=377 Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Survival — 10.0; 7.4 months — p=0.0096
Phase 2 N=12 Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
Leber Congenital Amaurosis
Primary: Number of Participants Experiencing Ocular or Non-ocular Adverse Events — 6; 6 participants
Phase 1 N=32 Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects
Healthy
Primary: Number of Healthy Subjects With AEs (Multiple Rising Dose Part) — 6; 5 participants